How change management determines whether AI becomes an enterprise capability or remains a permanent pilot.
The biopharma industry has never had a shortage of ambition when it comes to AI. What it has a shortage of is follow-through.
According to a December 2025 Deloitte report, only 22 percent of life sciences leaders report successfully scaling AI initiatives beyond pilots, and just 9 percent report achieving significant financial returns.
The problem isn’t the technology. The tools work. The problem is organizational, and it’s one the industry continues to underestimate.
Most biopharma change is vertical. AI is horizontal.
Biopharma organizations are experienced with change. Asset launches, system implementations, and functional reorganizations are difficult, but they are contained. They occur within a function, a program, or a geography. The underlying operating model remains largely intact.
AI doesn’t work that way.
It cuts horizontally across the enterprise, touching manufacturing, quality, regulatory, clinical, and commercial functions simultaneously. It doesn’t simply introduce new tools; it changes how evidence is interpreted, how risk is evaluated, and who is accountable for decisions supported by algorithmic systems. That’s a fundamentally different kind of change, and the playbooks organizations have relied on historically don’t fully address it.
There is also a cultural mismatch at the center of this challenge. Biopharma organizations are built around stability. Protocols are locked. Processes are designed for audit readiness. Change control exists for good reason.
AI systems operate differently. Models update as new data becomes available. Managing that tension requires structured lifecycle governance for AI models, including validation checkpoints, documentation standards, and defined escalation paths. Not because bureaucracy demands it, but because without those guardrails, teams simply will not trust the outputs even when the underlying technology performs as intended.
Most Organizations Can Prove AI Works. Far Fewer Can Make It Stick.
Most companies can demonstrate value in an AI pilot. The problem is what happens next.
Pilots prove that technology works. They rarely prove that the organization is prepared to use it at scale.
Three structural breakdowns tend to appear repeatedly when organizations attempt to move from experimentation to enterprise capability.
The first is messaging that focuses on features rather than workflow. Teams learn what a tool does, but no one shows them what work will change, which tasks can be discontinued, or how daily decision-making will be affected. Without that clarity, adoption remains superficial. People use the new system when required and revert to familiar workflows when oversight disappears.
The second structural breakdown is late governance. Regulatory, quality, and compliance teams are often engaged only after pilots demonstrate value. This positions them as gatekeepers rather than collaborators. Governance introduced after the fact creates friction. Governance embedded from the beginning creates confidence.
The third, and least discussed, is the accountability gap. Biopharma professionals remain personally responsible for the rigor and defensibility of their work. When AI assists in analysis or decision-making, that accountability does not transfer with it. It remains with the human.
When individuals are responsible for conclusions generated through systems they do not fully understand, control, or trust, quiet resistance becomes the rational response. Teams do not openly reject the technology. They simply return to familiar workflows.
Scaling AI Is Not a Technology Challenge. It’s a Workflow Design Challenge.
Workflow redesign is the most underinvested lever in AI adoption.
Layering AI tools onto existing processes rarely produces meaningful change. Organizations must map workflows honestly, remove redundant steps, and decide which tasks should be automated, simplified, or eliminated. If AI adds steps rather than removing them, adoption quickly disappears. This work is not primarily a technical challenge. It is organizational design.
Governance architecture must also be established before deployment, not after. This includes defining validation pathways, documentation standards, and clear boundaries around what AI informs, what it automates, and where human approval remains required. When these guardrails are clear, innovation moves faster because teams understand what is permitted.
Leadership alignment must be anchored in outcomes rather than aspiration. Statements such as “we are adopting AI” are not strategies. Transformation requires measurable objectives: faster development timelines, improved consistency of analysis, higher quality insights, or more efficient decision cycles.
Organizations must also address the skills gap directly. A GlobalData survey of 109 biopharma professionals found that 49 percent identified skill shortages as the leading barrier to digital transformation. These capabilities do not develop automatically. Companies need individuals who can operate across technical, scientific, regulatory, and commercial domains simultaneously.
The Real Competitive Question
The competitive question is no longer who experiments with AI. It’s who operationalizes it.
AI tools in biopharma are maturing quickly. Competitive advantage increasingly will not come from which platforms organizations purchase or which pilots they run. It will come from which organizations build the governance models, operating structures, and workflows necessary to use these technologies responsibly at scale.
Most organizations don’t lack the will to do this work. They lack the infrastructure and experience to do it well in a regulated environment where the cost of getting it wrong is high.
Technology vendors can deploy systems. Building the organizational capability to use them, and sustain that use over time, is a different kind of work entirely. At Opus Strategy, that is the work we do alongside leadership teams: translating AI ambition into the governance models, operating structures, and change programs that turn promising pilots into durable enterprise capability.